Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Invested Capital (2021 - 2025)

Amylyx Pharmaceuticals has reported Invested Capital over the past 5 years, most recently at $305.3 million for Q4 2025.

  • Quarterly results put Invested Capital at $305.3 million for Q4 2025, up 85.27% from a year ago — trailing twelve months through Dec 2025 was $305.3 million (up 85.27% YoY), and the annual figure for FY2025 was $305.3 million, up 85.27%.
  • Invested Capital for Q4 2025 was $305.3 million at Amylyx Pharmaceuticals, down from $332.0 million in the prior quarter.
  • Over the last five years, Invested Capital for AMLX hit a ceiling of $433.4 million in Q4 2023 and a floor of -$151.2 million in Q4 2021.
  • Median Invested Capital over the past 5 years was $221.2 million (2022), compared with a mean of $200.2 million.
  • Biggest five-year swings in Invested Capital: surged 398.83% in 2022 and later crashed 61.99% in 2024.
  • Amylyx Pharmaceuticals' Invested Capital stood at -$151.2 million in 2021, then skyrocketed by 325.32% to $340.6 million in 2022, then increased by 27.25% to $433.4 million in 2023, then crashed by 61.99% to $164.8 million in 2024, then surged by 85.27% to $305.3 million in 2025.
  • The last three reported values for Invested Capital were $305.3 million (Q4 2025), $332.0 million (Q3 2025), and $167.9 million (Q2 2025) per Business Quant data.